Clinical guideline recommendations for antipsychotic long-acting injections
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Long-acting injections (LAIs) of antipsychotic drugs were developed over 40 years ago in an attempt to improve the long-term treatment of schizophrenia. Aims: To review existing guidelines concerning antipsychotic use generally, and LAIs in particular, and how patients might be identified as potential candidates for LAI treatment. Method: Literature review. Results: Currently several first-generation and one second-generation antipsychotic LAIs are available, with others under development. Although the use of LAIs is widespread around the world, patterns of use vary widely. Important considerations regarding the use of LAIs include the indications for long-term pharmacotherapy in schizophrenia in general, the indications for LAIs, the risks associated with LAIs, the need to update guidelines and the issue of cost. Conclusions: The use of these injections in first-episode psychosis and treatment-refractory schizophrenia is not currently a focus of recommendations, but should be considered. Long-acting injections remain an underutilised option in many countries despite frequent non-adherence with oral medication and subsequent relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383
Low dose fluphenazine decanoate in maintenance treatment of schizophrenia
Kane, J. M., Rifkin, A., Quitkin, F., Nayak, D., Saraf, K., Ramos-Lorenzi, J. R., Klein, D. F., & Sachar, E. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90016-7 · Cited by 44
Self-citation
Cited by
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
Kane, J. M., Kishimoto, T., & Correll, C. U. (2013) · World Psychiatry · doi:10.1002/wps.20060 · Cited by 520
Self-citationKishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs150 · Cited by 395
Self-citationThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297
Kaplan, G., Casoy, J., & Zummo, J. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s53795 · Cited by 201
Llorca, P. M., Abbar, M., Courtet, P., Guillaume, S., Lancrenon, S., & Samalin, L. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-340 · Cited by 188
Kishimoto, T., Hagi, K., Nitta, M., Leucht, S., Olfson, M., Kane, J. M., & Correll, C. U. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx090 · Cited by 186
“Subgroup analyses were based on (1) country, (2) region (North-America, Western Europe, Asia or others), (3) publication year (published before 2000, from 2000 to 2009, 2010 or later), (4) pharmaceutical sponsorship, (5) data source (single institution, multiple institutions, large database studies, including nationwi…”
BackgroundSelf-citationKane, J. M., Kishimoto, T., & Correll, C. U. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.01.012 · Cited by 131
“those in many other countries [7].”
Self-citationPotkin, S., Bera, R., Zubek, D., & Lau, G. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-261 · Cited by 98
Long‐acting injectable antipsychotics in early psychosis: a literature review
Emsley, R., Chiliza, B., Asmal, L., Mashile, M., & Fusar‐Poli, P. (2013) · Early Intervention in Psychiatry · doi:10.1111/eip.12027 · Cited by 61
Sajatovic, M., Ross, R., Legacy, S. N., Correll, C. U., Kane, J. M., DiBiasi, F., Fitzgerald, H., & Byerly, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167394 · Cited by 44
“Although the 2004 APA schizophrenia guidelines generally recommended LAIs for patients who prefer an LAI or for those who are nonadherent,(16) newer guidelines recommend LAI SGAs as first-line treatment for schizophrenia and as maintenance treatment for bipolar disorder.(16,18,36) Although disadvantages of LAIs includ…”
BackgroundSelf-citationSamalin, L., Garnier, M., Auclair, C., & Llorca, P.-M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111935 · Cited by 23
“However, recent guidelines for the use and management of LAI antipsychotics in clinical practice evoke the possibility of using this formulation for patients with first-episode or recent-onset schizophrenia [8-12].”
Liu, C.-C., & Takeuchi, H. (2020) · CNS Drugs · doi:10.1007/s40263-019-00682-8 · Cited by 19
Morton, N. K., & Zubek, D. (2013) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20130215-01 · Cited by 16
Metadata
- Authors
- Kane, J. M., & Garcia-Ribera, C.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2009-11
- Volume
- 195
- Issue
- S52
- Pages
- s63-s67
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2134675761
- Cited by
- 147
- References
- 3
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.